NCT03916042View on ClinicalTrials.gov

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

April 23, 2019

Primary Completion Date

November 22, 2019

Study Completion Date

November 22, 2019

Conditions
Dry Eye
Interventions
DRUG

Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID

Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks

DRUG

Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID

Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks

Trial Locations (1)

01810

Andover Eye Associates, Andover

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY